HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hui-Wen Chang Selected Research

Nicotine

12/2019The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration.
11/2016Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
9/2011Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells.
3/2011Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced α9-nicotinic acetylcholine receptor upregulation in human breast cancer cells.
1/2010Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hui-Wen Chang Research Topics

Disease

32Neoplasms (Cancer)
12/2021 - 04/2006
20Infections
12/2024 - 07/2005
14Breast Neoplasms (Breast Cancer)
12/2021 - 01/2010
6Neoplasm Metastasis (Metastasis)
05/2020 - 08/2012
5Carcinogenesis
01/2023 - 01/2010
5Virus Diseases (Viral Diseases)
07/2021 - 04/2014
4COVID-19
06/2023 - 01/2020
4Diarrhea
08/2022 - 09/2018
4Adenocarcinoma of Lung
01/2018 - 08/2011
4Endometriosis
11/2016 - 02/2011
3Inflammation (Inflammations)
01/2023 - 12/2008
3Body Weight (Weight, Body)
02/2022 - 04/2012
3Triple Negative Breast Neoplasms
12/2021 - 04/2018
3Disease Progression
06/2018 - 09/2010
3Prostatic Neoplasms (Prostate Cancer)
09/2017 - 09/2010
2Sarcoma (Soft Tissue Sarcoma)
01/2023 - 10/2019
2Carcinoma (Carcinomatosis)
05/2020 - 11/2016
2Colonic Neoplasms (Colon Cancer)
07/2019 - 10/2012
2Ovarian Neoplasms (Ovarian Cancer)
04/2018 - 11/2016
2Human Influenza (Influenza)
04/2014 - 01/2011
2Hepatocellular Carcinoma (Hepatoma)
05/2013 - 08/2010
2Liver Neoplasms (Liver Cancer)
05/2013 - 08/2010
2Asthma (Bronchial Asthma)
03/2010 - 12/2008
1Classical Swine Fever (Swine Fever)
10/2023
1Communicable Diseases (Infectious Diseases)
01/2022
1Rheumatoid Arthritis
10/2021
1Hemolysis
04/2021
1Metaplasia
05/2020
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020
1Respiratory Tract Infections (Respiratory Tract Infection)
01/2020
1Melanoma (Melanoma, Malignant)
12/2019

Drug/Important Bio-Agent (IBA)

16Proteins (Proteins, Gene)FDA Link
10/2023 - 01/2010
13Messenger RNA (mRNA)IBA
01/2022 - 04/2006
11VaccinesIBA
02/2022 - 06/2010
5NicotineFDA Link
12/2019 - 01/2010
4Immunoglobulin M (IgM)IBA
12/2022 - 08/2008
4CytokinesIBA
01/2022 - 09/2012
4AntigensIBA
07/2021 - 07/2006
4Estrogens (Estrogen)FDA Link
01/2019 - 03/2011
3Immunoglobulin G (IgG)IBA
12/2022 - 10/2021
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022 - 04/2006
3Interleukin-8 (Interleukin 8)IBA
01/2022 - 04/2006
3Peptides (Polypeptides)IBA
10/2021 - 06/2018
3Biomarkers (Surrogate Marker)IBA
05/2020 - 01/2019
3Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
12/2019 - 01/2010
3Cadherins (E-Cadherin)IBA
12/2019 - 01/2018
3Cisplatin (Platino)FDA LinkGeneric
10/2019 - 01/2012
3Adenosine Triphosphatases (ATPase)IBA
04/2019 - 07/2011
3Cholinergic ReceptorsIBA
11/2016 - 03/2011
3Ethanol (Ethyl Alcohol)IBA
05/2013 - 07/2002
2EpitopesIBA
10/2023 - 01/2011
2AntibodiesIBA
10/2023 - 01/2021
2ParaffinIBA
10/2023 - 10/2019
2EnzymesIBA
01/2023 - 08/2012
2ChAdOx1 nCoV-19IBA
02/2022 - 02/2022
2Antiviral Agents (Antivirals)IBA
01/2022 - 04/2014
2CurcuminIBA
12/2021 - 05/2013
2Hyaluronan SynthasesIBA
10/2021 - 01/2019
2PolyphenolsIBA
01/2021 - 03/2011
2TeaIBA
01/2021 - 03/2011
2ErbB Receptors (EGF Receptor)IBA
01/2020 - 01/2018
2PaxillinIBA
12/2019 - 08/2012
2Focal Adhesion Protein-Tyrosine KinasesIBA
12/2019 - 08/2012
2apioleIBA
07/2019 - 10/2012
2TamoxifenFDA LinkGeneric
11/2018 - 11/2013
2Estrogen ReceptorsIBA
10/2018 - 09/2011
2DNA (Deoxyribonucleic Acid)IBA
08/2018 - 09/2010
2Small Interfering RNA (siRNA)IBA
04/2018 - 08/2012
2MicroRNAs (MicroRNA)IBA
11/2016 - 01/2013
2Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA
05/2013 - 08/2012
2Hormones (Hormone)IBA
05/2012 - 03/2011
2Glycoproteins (Glycoprotein)IBA
12/2010 - 06/2010
1Formaldehyde (Formol)FDA Link
10/2023
1COVID-19 VaccinesIBA
06/2023
1robenacoxibIBA
01/2023
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2023
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2023
1Thomsen-Friedenreich antibodiesIBA
12/2022
1Lactic Acid (Lactate)FDA LinkGeneric
01/2022
1SaltsIBA
12/2021
1Cyclin DIBA
12/2021
1Hyaluronic Acid (Hyaluronan)IBA
10/2021
1AutoantibodiesIBA
10/2021
1Adenosine Monophosphate (AMP)IBA
04/2021
1GalNAc- 1- 3- (Fuc- 1- 2)Gal- 1- 3- GlcNAc- 1- 3- Gal- 1- 4- Glc- PAIBA
01/2021
1epigallocatechin gallate (epigallocatechin-3-gallate)IBA
01/2021
1Globo-HIBA
01/2021
1Proline Oxidase (Proline Dehydrogenase)IBA
01/2021
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2020
1Oncogene Proteins (Oncogene Protein)IBA
01/2020
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
12/2019
1Complex MixturesIBA
12/2019
1CateninsIBA
12/2019

Therapy/Procedure

9Therapeutics
12/2024 - 08/2012
3Drug Therapy (Chemotherapy)
12/2021 - 09/2010
1Renal Dialysis (Hemodialysis)
06/2023
1Oral Administration
08/2022
1Heterologous Transplantation (Xenotransplantation)
10/2021
1Immunotherapy
01/2021
1Aftercare (After-Treatment)
01/2021